- Learn more about EpiCept’s approach to pain
-
View Approach to Pain
Overview
EpiCept is taking a new approach to treating both acute and chronic pain by targeting peripheral nerve receptors using analgesics delivered topically. These product candidates are designed to block the ability of peripheral nerve receptors to transmit pain messages to the brain, which in turn will provide significant pain relief, with fewer adverse side effects, fewer drug to drug interactions and lower potential for abuse than systemically delivered analgesics.
EpiCept has six pain product candidates in clinical development, including three that are ready to enter, or have entered, Phase IIb or Phase III clinical trials, and three that have completed initial Phase II clinical trials.
Pain Product Candidates
Earlier Stage Pain Product Candidates
Deep Late Stage Development Pipeline
